Arginase Deficiency Therapeutics Market Overview
The Arginase Deficiency Therapeutics Market was valued at USD 500 million in 2024 and 2025 and is projected to reach USD 1.5 billion by 2035, expanding at a CAGR of 10.6% during the 2026–2035 forecast period. Market growth is being supported by increasing awareness and diagnosis of rare diseases, advancements in gene therapy and enzyme replacement therapy, limited treatment options, and growing investment in rare disease research.
North America is expected to remain the leading regional market, valued at USD 250 million in 2024 and projected to reach USD 750 million by 2035. Europe is also expected to witness steady growth, while Asia-Pacific is anticipated to expand significantly as healthcare access, rare-disease awareness, and government initiatives improve.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/sample-request?id=600872
Key Companies in the Arginase Deficiency Therapeutics Market
Novartis
Cure Rare Disease
Ultragenyx Pharmaceutical
Genzyme
Alder BioPharmaceuticals
Sangamo Therapeutics
Research Pharmaceutical Services
Biomarin Pharmaceutical
Lysogene
Amgen
Sanofi
Retrophin
AstraZeneca
The Arginase Deficiency Therapeutics Market is driven by the growing recognition of rare diseases and increasing research funding aimed at addressing unmet medical needs. Advancements in gene therapies and enzyme replacement therapies are expanding treatment possibilities, while increasing clinical research and patient advocacy are improving awareness of arginase deficiency. Personalized treatment approaches and supportive regulatory frameworks for rare-disease therapies are also creating opportunities for market expansion.
The market is segmented by therapeutic approach, formulation type, patient age group, route of administration, and region. Therapeutic approaches include Enzyme Replacement Therapy, Gene Therapy, and Symptomatic Treatment. Enzyme Replacement Therapy represented the leading approach, valued at USD 200 million in 2024 and projected to reach USD 600 million by 2035. Formulation types include Injectable, Oral, and Infusion, while patient groups comprise Pediatric, Adult, and Geriatric populations. Routes of administration include Subcutaneous, Intravenous, and Oral.
Recent Developments and Market Trends:
Ultragenyx Pharmaceutical announced a strategic collaboration with Cure Rare Disease in March 2025 to accelerate research and development of arginase deficiency gene therapy programs.
Biomarin Pharmaceutical announced a contract with Research Pharmaceutical Services in May 2025 to support multicenter clinical trials for an arginase deficiency therapy candidate.
Sanofi announced a collaboration with Sangamo Therapeutics in February 2025 to explore gene-editing approaches for arginase deficiency therapy development.
Advances in gene therapy are creating new possibilities for addressing the underlying genetic causes of arginase deficiency.
Growing investment in rare-disease research is encouraging the development of innovative therapeutic approaches.
Increasing awareness among healthcare professionals and patient advocacy groups is supporting earlier diagnosis and improving access to treatment.
Reasons to Buy the Report:
Understand the market size, growth rate, and forecast outlook of the global Arginase Deficiency Therapeutics Market.
Analyze major therapeutic approaches including enzyme replacement therapy, gene therapy, and symptomatic treatment.
Evaluate formulation types such as injectable, oral, and infusion therapies.
Assess market opportunities across pediatric, adult, and geriatric patient populations.
Identify leading companies and understand the competitive landscape.
Examine regional growth opportunities across North America, Europe, Asia-Pacific, South America, and the Middle East and Africa.
Understand the impact of gene therapy advancements, rare-disease awareness, personalized medicine, and research collaborations on future market growth.
Future Outlook:
The Arginase Deficiency Therapeutics Market is expected to experience strong growth through 2035 as awareness of rare diseases increases and innovative treatment approaches continue to advance. Gene therapy and enzyme replacement therapy are likely to remain important areas of development, while personalized treatment strategies and expanding clinical research may improve patient outcomes. Increasing investment in rare-disease programs and supportive regulatory environments should create additional opportunities for pharmaceutical and biotechnology companies.
➤➤Explore Our Latest Related Reports:
